InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Alcidion Group Limited (ASX:ALC)

ALERT: Price-sensitive ASX Announcement for ALC
Current share price for ALC : $0.100 -0.04 (-28.57%)+
Announcement
Release
15 Jan 2026 8:46AM
Price at Release
$0.140
Full Release
download
Summary
In Q2 FY26, Alcidion Group Limited reported significant progress with a total contract value sales of $15.4 million, driven by new contracts and expansions, including enhancements to the Miya Precision platform for Leidos servicing the Australian Defence Force. The company achieved a contracted revenue of $43.1 million, marking a 40% increase from the previous period, and maintained a cash balance of $14.2 million with no debt. Despite an operating cash outflow of $1.9 million, the cash receipts amounted to $8.5 million. Alcidion was selected as the preferred supplier for University Hospitals Sussex NHS Foundation Trust's new EPR solution, a potential $35 million contract. The company anticipates positive EBITDA and operating cash flow for FY26, supported by a strong financial position and disciplined cost management.
Key Points
  • Q2 FY26 new total contract value (TCV) sales of $15.4M.
  • Operating cash outflow for Q2 FY26 was $1.9M with cash receipts of $8.5M.
  • End of Q2 FY26 contracted revenue was $43.1M, a 40% increase from the prior period.
  • Cash balance at the end of Q2 FY26 was $14.2M with no debt.
  • Alcidion was selected as the preferred supplier for University Hospitals Sussex NHS Foundation Trust's new EPR solution.
  • Q2 FY26 guidance anticipates positive EBITDA and operating cash flow.
  • Payments to related parties totaled $0.26M for Q2 FY26.
  • Alcidion's Miya Precision platform expanded for the Australian Defence Force project with Leidos.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.